Slide 1: Corporate Presentation
Corporate Presentation May 2026
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptio
Slide 3: Harrow. We are Ophthalmic Pharma.
Harrow. We are Ophthalmic Pharma. Diversified Provider of Ophthalmic Disease Management Solutions in North America Key revenue drivers are best- Scalable commercial platform Largest U.S. portfolio of prescription ophthalmic in-class products with large with an innovative market products broadly cove
Slide 4: Investment Highlights
Investment Highlights Durable Revenue Drivers Strengthening an Accelerating Growth Profile Dry Eye Disease Ocular Anesthesia 25% NRx growth Q1 ’26 vs Q4 ‘25 18% Unit demand growth Q1 ’26 vs Q1 ‘25 ▪ 11% TRx growth Q1 ’26 vs Q4 ’25 ▪ March 2026 demand up 34% vs. March 2025 ▪ 12% prescriber growth Q1
Slide 5: 2026–2029 Commercial Launches & Pipeline
2026–2029 Commercial Launches & Pipeline Launching at Least One Product Every Year Through 2029 Near Term Commercial Launches Topical Steroid LUCENTIS Anti-VEGF Biosimilar EYLEA Anti-VEGF Biosimilar Q3 2026 Launch July 2026 Launch 2027 Launch R&D Pipeline G-MELT YOCHIL H-NO8 Ketamine + Midazolam ODT
Slide 6: Financials & Outlook
Financials & Outlook 6 Corporate Presentation | May 2026
Slide 7: 2026 Key Financial Metrics (in thousands)
2026 Key Financial Metrics (in thousands) Five years of consistent revenue and EBITDA expansion Q1 2026 Key Metrics Q1 2026 Key Metrics FIVE-YEAR TRACK RECORD REVENUE ADJ. EBITDA¹ CONSOL IDATED REV ENUE $44.2M $(12.7)M $ in millions 41% 5-Yr CAGR PRODUCT RE VENUE $400M $357.5M Midpoint VEVYE $20.9M*
Slide 8: 2026 Financial Guidance Phasing
2026 Financial Guidance Phasing Q1 Q2 Q3 Q4 2024 Actual ~17% ~25% ~25% ~33% 2025 Actual ~18% ~23% ~26% ~33% 2026 Estimate 2026 quarterly revenue mix expected to be modestly more weighted toward H2 vs. 2024 and 2025 • Buy & Bill products working • IHEEZO loses pass-through status • Q3 typically bring
Slide 9: Dry Eye Disease
Dry Eye Disease • VEVYE 9 Corporate Presentation | May 2026
Slide 10: VEVYE — Best-in-Class for Dry Eye Disease
VEVYE — Best-in-Class for Dry Eye Disease The first and only water-free cyclosporine for the signs and symptoms of dry eye disease MARKET OPPORTUNITY DED patient funnel ~22x More cyclosporine delivered into the cornea vs. Restasis Preclinical ex-vivo corneal penetration study data 37.1M Patients glo
Slide 11: VEVYE Q1 2026 Key Metrics
VEVYE Q1 2026 Key Metrics1 ~25% ~11% +12% 14% NRx growth TRx growth Prescriber growth Market Share Q1 '26 vs Q4 '25 Q1 ’26 vs Q4 ‘25 Q1 '26 vs Q4 '25 As of end of March ‘26 Quarterly revenue Q1 Highlights U.S. net revenue | Q1 ‘25 → Q1 ‘26 NRx + refills = durable revenue $30M Each new covered script
Slide 12: Ocular Anesthesia
Ocular Anesthesia • IHEEZO 12 Corporate Presentation | May 2026
Slide 13: IHEEZO Overview
IHEEZO Overview • First-in-class: only branded ocular anesthetic approved in the U.S. in nearly 14 years Sterile, single-patient-use, • Large TAM: >14M annual U.S. ocular procedures require surface anesthesia physician-administered, ophthalmic gel preparation for • Reimbursement unlocked: permanent
Slide 14: IHEEZO Total Addressable Market
IHEEZO Total Addressable Market ~14M+ Estimated Annual U.S. In-Office Procedures | Standard of Care requires ocular surface anesthesia Main IHEEZO Applicable Procedures ~10M+ ✓ IHEEZO ~1.5M+ ✓ IHEEZO ~1M+ ✓ IHEEZO ~700K ✓ IHEEZO Intravitreal Laser Gonioscopy Foreign Body Injections Procedures (Proce
Slide 15: IHEEZO Q1 2026 Key Metrics
IHEEZO Q1 2026 Key Metrics1 +18% +49% 85.5% ~82% Unit demand growth Growth in new accounts Re-order rate Retina-driven volume Q1 ‘26 vs Q1 ‘25 Q1 ’26 vs Q1 ‘25 Q1 ‘26 Share of Q1 ‘26 units Q1 Highlights Quarterly customer unit demand2 +18% YoY Net pricing lift FY 2024: 128,585 units → FY 2025: 201,2
Slide 16: IHEEZO Accelerating Growth
IHEEZO Accelerating Growth Four key initiatives to drive revenue acceleration 01 02 03 04 Unlocking the Full Retina-Specific Multi-Unit Improved In-Office Market Clinical Data Packaging Net Pricing • Growing retina share • Key Investigator Initiated Trial • 5-unit packaging designed • Estimated 20-2
Slide 17: Injectable Corticosteroid
Injectable Corticosteroid • TRIESENCE 17 Corporate Presentation | May 2026
Slide 18: TRIESENCE Overview
TRIESENCE Overview The only FDA-approved preservative-free (PF) synthetic corticosteroid Expansion into Injectable suspension (triamcinolone acetonide 40 mg/mL) with separate reimbursement in every ocular inflammation traditional care setting1 7M+ Annual potential Regulatory U.S. use cases in ocular
Slide 19: TRIESENCE Q1 2026 Key Metrics
TRIESENCE Q1 2026 Key Metrics +136% 44% ~28% 6Qs Unit volume growth Volume from Ocular Surgery Growth in new accounts Consecutive growth Q1 ‘26 vs Q1 ‘25 Q1 ‘26 Q1 ’26 vs Q4 ‘25 Since re-launch Quarterly unit demand1 +250% over 6Q Q1 HIG HLIG HTS Unit demand per quarter | Q1 ‘25 → Q1 ‘26 Ocular infl
Slide 20: Anti-VEGFs
Anti-VEGFs • BYOOVIZ • OPUVIZ 20 Corporate Presentation | May 2026
Slide 21: Best-in-Class Anti-VEGF Biosimilars
Best-in-Class Anti-VEGF Biosimilars Two FDA-approved ophthalmic biosimilars acquired from Samsung Bioepis — addressing the largest market in Ophthalmology ranibizumab-nuna • 0.05 mL injection aflibercept-yszy • 0.05 mL injection First FDA-approved LUCENTIS® biosimilar FDA-approved EYLEA® biosimilar
Slide 22: U.S. Ophthalmic Market Share-Anti-VEGFs
U.S. Ophthalmic Market Share-Anti-VEGFs A defined market opportunity met with a differentiated, relationship-led commercial strategy U.S. Anti-VEGF Market Harrow's Differentiated Launch Strategy Competing on relationships and value ~8.5M units annually | >$4.2B Medicare Part B spend Account-Level Re
Slide 23: Specialty and Access+
Specialty and Access+ 23 Corporate Presentation | May 2026
Slide 24: Specialty and Access+
Specialty and Access+ Specialty Steroids, NSAIDs, and Antihistamine, Antibiotics, and Anti-Inflammatories Antibiotic + Steroid Combination Q1 2026 HIGHLIGHTS • IOPIDINE® J-Code granted o Enables separate reimbursement and expands commercial access • Unlocking value from 2 specialty products in large
Slide 25: IOPIDINE — Reimbursement Inflection Unlocking an Underserved Market
IOPIDINE® — Reimbursement Inflection Unlocking an Underserved Market The only FDA-approved therapy to prevent procedural IOP spikes CLI NI CA L EVID ENCE MARKET OPPORTUNITY Indication Only FDA-approved product to prevent IOP spikes following in-office laser procedures 1.5M*+ ~91% J-Code ~91% risk re
Slide 26: Pipeline
Pipeline 26 Corporate Presentation | May 2026
Slide 27: Harrow's Pipeline
Harrow’s Pipeline Product Indication Stage of Development Potential Launch Development G-MELT (MELT-300) Procedural (Ketamine + End of Phase 3 2028 Internal Sedation Midazolam ODT) YOCHIL (MELT-210) Sedation, Anxiolysis, and Clinical 2028 Internal (Midazolam ODT) Amnesia H-N08 Uveitis, (Triamcinolon
Slide 28: G-MELT — IV- & Opioid-Free Procedural Sedation
G-MELT — IV- & Opioid-Free Procedural Sedation Fixed dose sublingual tablet combining 3 mg midazolam + 50 mg ketamine (non-opioid), two known and proven FDA-approved molecules in a novel form WHAT MAKES G-MELT DIFFERENT P A T H T O L A U N C H Zydis® sublingual technology Dissolves in seconds under
Slide 29: Other Pipeline Programs
Other Pipeline Programs YOCHIL H-N08 CR-01 Formerly MELT-210 Triamcinolone Acetonide Conjunctival Delivery Device 505(b)2 2028 Launch CMC Optimization H2 28 / H1 29 Launch Proof of Concept 2029 Launch Oral dissolving tablet — 3 mg midazolam TRIESENCE next-gen in prefilled syringe Sustained-release d
Slide 30: Mike Biega
1A Burton Hills Blvd., Suite 200 Nashville, Tennessee 37215 Harrow.com Mike Biega Vice President of Investor Relations & Communications mbiega@harrowinc.com Direct: 617-913-8890 30 Corporate Presentation | May 2026